Refractory depression - cost-effectiveness of radically open dialectical behaviour therapy: findings of economic evaluation of RefraMED trial.
Refractory depression
chronic depression
cost-effectiveness analysis
radically open dialectical behaviour therapy (RO DBT)
treatment-resistant depression
Journal
BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
30
7
2019
Statut:
ppublish
Résumé
Refractory depression is a major contributor to the economic burden of depression. Radically open dialectical behaviour therapy (RO DBT) is an unevaluated new treatment targeting overcontrolled personality, common in refractory depression, but it is not yet known whether the additional expense of RO DBT is good value for money.AimsTo estimate the cost-effectiveness of RO DBT plus treatment as usual (TAU) compared with TAU alone in people with refractory depression (trial registration: ISRCTN85784627). We undertook a cost-effectiveness analysis alongside a randomised trial evaluating RO DBT plus TAU versus TAU alone for refractory depression in three UK secondary care centres. Our economic evaluation, 12 months after randomisation, adopted the perspective of the UK National Health Service (NHS) and personal social services. It evaluated cost-effectiveness by comparing the net cost of RO DBT with the net gain in quality-adjusted life-years (QALYs), estimated using the EQ-5D-3L measure of health-related quality of life. The additional cost of RO DBT plus TAU compared with TAU alone was £7048 and was associated with a difference of 0.032 QALYs, yielding an incremental cost-effectiveness ratio (ICER) of £220 250 per QALY. This ICER was well above the National Institute for Health and Care Excellence (NICE) upper threshold of £30 000 per QALY. A cost-effectiveness acceptability curve indicated that RO DBT had a zero probability of being cost-effective compared with TAU at the NICE £30 000 threshold. In its current resource-intensive form, RO DBT is not a cost-effective use of resources in the UK NHS.Declaration of interestR.H. is co-owner and director of Radically Open Ltd, the RO DBT training and dissemination company. D.K. reports grants outside the submitted work from the National Institute for Health Research (NIHR). T.L. receives royalties from New Harbinger Publishing for sales of RO DBT treatment manuals, speaking fees from Radically Open Ltd, and a grant outside the submitted work from the Medical Research Council. He was co-director of Radically Open Ltd between November 2014 and May 2015 and is married to Erica Smith-Lynch, the principal shareholder and one of two directors of Radically Open Ltd. H.O'M. reports personal fees outside the submitted work from the Charlie Waller Institute and Improving Access to Psychological Therapy. S.R. provides RO DBT supervision through her company S C Rushbrook Ltd. I.R. reports grants outside the submitted work from NIHR and Health & Care Research Wales. M. Stanton reports personal fees outside the submitted work from British Isles DBT Training, Stanton Psychological Services Ltd and Taylor & Francis. M. Swales reports personal fees outside the submitted work from British Isles DBT Training, Guilford Press, Oxford University Press and Taylor & Francis. B.W. was co-director of Radically Open Ltd between November 2014 and February 2015.
Sections du résumé
BACKGROUND
BACKGROUND
Refractory depression is a major contributor to the economic burden of depression. Radically open dialectical behaviour therapy (RO DBT) is an unevaluated new treatment targeting overcontrolled personality, common in refractory depression, but it is not yet known whether the additional expense of RO DBT is good value for money.AimsTo estimate the cost-effectiveness of RO DBT plus treatment as usual (TAU) compared with TAU alone in people with refractory depression (trial registration: ISRCTN85784627).
METHOD
METHODS
We undertook a cost-effectiveness analysis alongside a randomised trial evaluating RO DBT plus TAU versus TAU alone for refractory depression in three UK secondary care centres. Our economic evaluation, 12 months after randomisation, adopted the perspective of the UK National Health Service (NHS) and personal social services. It evaluated cost-effectiveness by comparing the net cost of RO DBT with the net gain in quality-adjusted life-years (QALYs), estimated using the EQ-5D-3L measure of health-related quality of life.
RESULTS
RESULTS
The additional cost of RO DBT plus TAU compared with TAU alone was £7048 and was associated with a difference of 0.032 QALYs, yielding an incremental cost-effectiveness ratio (ICER) of £220 250 per QALY. This ICER was well above the National Institute for Health and Care Excellence (NICE) upper threshold of £30 000 per QALY. A cost-effectiveness acceptability curve indicated that RO DBT had a zero probability of being cost-effective compared with TAU at the NICE £30 000 threshold.
CONCLUSIONS
CONCLUSIONS
In its current resource-intensive form, RO DBT is not a cost-effective use of resources in the UK NHS.Declaration of interestR.H. is co-owner and director of Radically Open Ltd, the RO DBT training and dissemination company. D.K. reports grants outside the submitted work from the National Institute for Health Research (NIHR). T.L. receives royalties from New Harbinger Publishing for sales of RO DBT treatment manuals, speaking fees from Radically Open Ltd, and a grant outside the submitted work from the Medical Research Council. He was co-director of Radically Open Ltd between November 2014 and May 2015 and is married to Erica Smith-Lynch, the principal shareholder and one of two directors of Radically Open Ltd. H.O'M. reports personal fees outside the submitted work from the Charlie Waller Institute and Improving Access to Psychological Therapy. S.R. provides RO DBT supervision through her company S C Rushbrook Ltd. I.R. reports grants outside the submitted work from NIHR and Health & Care Research Wales. M. Stanton reports personal fees outside the submitted work from British Isles DBT Training, Stanton Psychological Services Ltd and Taylor & Francis. M. Swales reports personal fees outside the submitted work from British Isles DBT Training, Guilford Press, Oxford University Press and Taylor & Francis. B.W. was co-director of Radically Open Ltd between November 2014 and February 2015.
Identifiants
pubmed: 31352916
pii: S2056472419000577
doi: 10.1192/bjo.2019.57
pmc: PMC6669879
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e64Références
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
J Health Serv Res Policy. 1998 Oct;3(4):233-45
pubmed: 10187204
Health Econ. 1999 May;8(3):257-61
pubmed: 10348420
Health Aff (Millwood). 1999 Sep-Oct;18(5):163-71
pubmed: 10495604
J Clin Psychiatry. 2002 Nov;63(11):963-71
pubmed: 12444808
J Occup Environ Med. 2003 Feb;45(2):156-74
pubmed: 12625231
Int Clin Psychopharmacol. 2004 May;19(3):125-34
pubmed: 15107654
Health Econ. 2004 Dec;13(12):1203-10
pubmed: 15386669
Br J Psychiatry. 2005 Aug;187:106-8
pubmed: 16055820
Health Technol Assess. 2006 Sep;10(35):iii, ix-xii, 1-117
pubmed: 16959171
Eur Neuropsychopharmacol. 2007 Nov;17(11):696-707
pubmed: 17521891
Int Clin Psychopharmacol. 2008 May;23(3):120-9
pubmed: 18408526
J Consult Clin Psychol. 2008 Dec;76(6):966-78
pubmed: 19045965
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Value Health. 2011 Jun;14(4):475-82
pubmed: 21669372
Psychother Psychosom. 2012;81(6):356-65
pubmed: 22964561
J R Soc Med. 2014 Apr;107(4):135-7
pubmed: 24692410
Br J Psychiatry. 2014 Sep;205(3):236-43
pubmed: 24855127
Int J Eat Disord. 2015 Jan;48(1):123-32
pubmed: 25346237
BMJ Open. 2015 Jul 17;5(7):e008857
pubmed: 26187121
Stat Med. 2018 Jun 30;37(14):2252-2266
pubmed: 29682776
Br J Psychiatry. 2019 Jul 18;:1-9
pubmed: 31317843
Health Econ. 1994 Sep-Oct;3(5):309-19
pubmed: 7827647
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889